Developing a blood test to detect Lyme disease earlier
Lyme disease symptoms can resemble other illnesses, while antibody tests may be falsely negative in the first weeks of infection. Early treatment usually leads to rapid recovery, but some patients treated later have already suffered long-term damage to their nervous system or joints.
Aces Diagnostics is developing LYMESEEK, a blood test that combines biomarkers with machine learning to detect Lyme disease earlier. Designed to run on existing laboratory equipment, it aims to help clinicians make earlier treatment decisions.
What stands out about Aces Diagnostics
Company-reported peer-reviewed study found 90% sensitivity and 93% specificity in a 467-sample training and validation cohort.
Exclusively licensed the LymeSeek multiplexed immunoassay, according to the Flinn Foundation's 2026 company directory.
Completed four FDA pre-submissions that aligned the company with regulatory expectations ahead of planned pivotal studies.
Partnered with Protavio to develop the IVD-grade assay kit and Repado to build software incorporating its diagnostic algorithm.
Bay Area Lyme Ventures announced an investment in Aces Diagnostics in September 2025; the amount was not disclosed.
Team won an ADLM 2025 Distinguished Abstract Award for its single-tier Lyme diagnostic research using machine learning.
Co-founder Todd Snowden previously built and exited a diagnostics company, according to the company's leadership biography.
Co-founder Monica Embers, PhD, is a Tulane Lyme researcher and director of vector-borne disease research.
Get a curated pipeline of healthcare and life sciences startups aligned with your investment thesis.